ReviewClinical cardiology2022
Myocardial viability assessment and utility in contemporary management of ischemic cardiomyopathy.
Review in Clinical cardiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 20 citations in OpenAlex.
- Myocardial fibrosis and viability: the role of imaging and biomarkers in patients with chronic total occlusion on coronary angiography.Biochemia medica · 2026Review
- Application of low-dose "one-stop" myocardial computed tomography perfusion imaging in coronary artery disease.Quantitative imaging in medicine and surgery · 2026Article
- Comparison of surgical outcomes in patients with heart failure with reduced ejection fraction combined with moderate ischemic mitral regurgitation: a single-center retrospective study.Journal of thoracic disease · 2025Article
- Feasibility, Added Value, and Radiation Dose of Combined Coronary CT Angiography and Stress Dynamic CT Myocardial Perfusion Imaging in Moderate Coronary Artery Disease: A Real-World Study.Journal of cardiovascular development and disease · 2025Article
- Cardiac resynchronization therapy via left bundle branch pacing in heart failure with complete left bundle branch block: is the defibrillator needed?Frontiers in cardiovascular medicine · 2025Article
- A Novel Approach to Identifying Hibernating Myocardium Using Radiomics-Based Machine Learning.Cureus · 2024Article
- Surgical Management of Ischemic Cardiomyopathy Patients with Severe Left Ventricular Dysfunction: Is It Time to Reconsider Revascularization Surgery?Journal of cardiovascular development and disease · 2024Review
- Determination of viable myocardium through delayed enhancement cardiac magnetic resonance imaging combined withThe international journal of cardiovascular imaging · 2024Article
- Multimodality Imaging in Advanced Heart Failure for Diagnosis, Management and Follow-Up: A Comprehensive Review.Journal of clinical medicine · 2023Review
- Understanding the role of coronary artery revascularization in patients with left ventricular dysfunction and multivessel disease.Heart failure reviews · 2023Review
- Revascularization and Left Ventricular Dysfunction for ICD Eligibility.Life (Basel, Switzerland) · 2023Review
- Myocardial Viability Testing in the Management of Ischemic Heart Failure.Life (Basel, Switzerland) · 2022Review
- Myocardial viability assessment and utility in contemporary management of ischemic cardiomyopathy.Clinical cardiology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn clinical practice, we encounter ischemic cardiomyopathy (ICM) with underlying viable, dysfunctional myocardium on a regular basis. Evidence from the Surgical Treatment for Ischemic Heart failure (STICH) and its Extension Study is supportive of improved outcomes with coronary revascularization, irrespective of myocardial viable status. However, Dobutamine stress echocardiography (DSE) and single-photon emission computed tomography (SPECT), used in STICH to assess myocardial viability may fail to distinguish hibernating myocardium from scar due to suboptimal image resolution and poor tissue characterization. HYPOTHESIS: Cardiac magnetic resonance (CMR) and positron emission tomography (PET) can precisely quantify myocardial scar and identify metabolically active, viable myocardium respectively. Unlike DSE and SPECT, CMR and PET allow examining myocardial status as a contiguous spectrum from viable to partially viable myocardium with varying degrees of subendocardial scar and nonviable myocardium with predominantly transmural scar, the therapeutic and prognostic determinants of ICM.
methodsUnder the guidance of CMR and PET imaging, myocardium can be distinguished viable from partially viable with subendocardial scar and predominantly transmural scar. In ICM, optimal medical therapy and coronary revascularization of viable/partially viable myocardium but not transmural scar may improve outcomes in patients with acceptable procedural risk.
resultsCoronary revascularization of partially viable and viable myocardial territory may improve clinical outcomes by preventing future ischemic, infarct events and further worsening of left ventricular remodeling and function.
conclusionsWhen deciding if coronary revascularization is appropriate in a patient with ICM, it is essential to take a patient-tailored, comprehensive approach incorporating myocardial viability, ischemia, and scar data with others such as procedural risk, and patient's comorbidities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.